Рак молочной железы

Sylvester Earns BCRF Award to Develop AI-Powered Breast Cancer Survivorship Platform

Sylvester Earns BCRF Award to Develop AI-Powered Breast Cancer Survivorship Platform Oncodaily

Scientists find breast cancer cells hiding behind protective “shields”

Researchers have mapped breast tumors in striking detail and uncovered hidden pockets of dormant cancer cells that may help explain why cancer can return after treatment. Unlike rapidly dividing cells, these quiet cells can essentially hibernate, allowing them to evade chemotherapy and reactivate later. The team found…

A Blood Test, Not a Scan, Now Triggers This Breast Cancer Treatment Switch Under Accelerated Approval

A Blood Test, Not a Scan, Now Triggers This Breast Cancer Treatment Switch Under Accelerated Approval Medical Daily

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

FDA Grants Accelerated Approval to a New Breast Cancer Treatment Medical Dialogues

Machine learning predicts CDK4/6 inhibitor outcomes in metastatic breast cancer

Machine learning predicts CDK4/6 inhibitor outcomes in metastatic breast cancer Bioengineer.org

Oncology Experts Highlight Landmark FDA Approval of Camizestrant in HR+/HER2- Advanced Breast Cancer

Oncology Experts Highlight Landmark FDA Approval of Camizestrant in HR+/HER2- Advanced Breast Cancer oncodaily.com

FDA Approves Camizestrant Despite Negative ODAC Vote: What It Means for ESR1-Mutated Breast Cancer

FDA Approves Camizestrant Despite Negative ODAC Vote: What It Means for ESR1-Mutated Breast Cancer Onco'Zine

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Business Wire

FDA OKs Etcamah for advanced breast cancer

The FDA has granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. The approval for camizestrant (Etcamah, AstraZeneca) is dependent on the detection of an ESR1 mutation during aromatase…

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

FDA Grants Accelerated Approval to a New Breast Cancer Treatment The Well News

<![CDATA[FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer]]>

AI May Help Identify Breast Cancers Missed by Mammograms, But Clinical Benefit Remains Uncertain - UCLA Health - Oncodaily

AI May Help Identify Breast Cancers Missed by Mammograms, But Clinical Benefit Remains Uncertain - UCLA Health Oncodaily

Angela Hernandez Shares Her Breast Cancer Story | BCRF

Angela Hernandez Shares Her Breast Cancer Story | BCRF Breast Cancer Research Foundation | BCRF

Interpreting Frontline ADC Trial Data in Metastatic Triple-Negative Breast Cancer

Interpreting Frontline ADC Trial Data in Metastatic Triple-Negative Breast Cancer Oncology Nursing News

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms, and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram, but there are still many significant limitations…